Factory 99% Imatinib Mesylate Powder CAS 220127-57-1 Anti-Cancer Imatinib Mesylate

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A267
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Imatinib Mesylate
• CAS: 220127-57-1
• Appearance: White Powder
• Assay: 99%
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 100g
• Function: Anti-Cancer
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

Product Name	Imatinib Mesylate
Appearance	White Powder
CAS NO.	220127-57-1
Molecular Formula	C29H31N7O·CH4SO3
Storage	Keep in a cool, dry, dark location

 

Imatinib Mesylate, also known as STI571 or Glivec, is an orally bioavailable imatinib mesylate salt. It is a reversible and selective tyrosine kinase inhibitor that targets specific kinase proteins involved in cell signaling and proliferation.

 

 

1. Cancer Treatment: Imatinib Mesylate is primarily used for the treatment of chronic myeloid leukemia (CML) and certain types of gastrointestinal stromal tumors (GIST). It is particularly effective in targeting the BCR-ABL fusion protein in CML and the KIT and PDGFR proteins in GIST.
2. Pharmaceutical Formulations: It is formulated as tablets or capsules for oral administration and is typically prescribed as a long-term treatment regimen.
3. Combination Therapy: In some cases, Imatinib Mesylate may be used in combination with other therapies or medications to enhance treatment efficacy and outcome.

1. Tyrosine Kinase Inhibition: Imatinib Mesylate inhibits the activity of tyrosine kinases, such as BCR-ABL, KIT, and PDGFR, which are involved in the regulation of cell growth, proliferation, and survival. By inhibiting these kinases, it disrupts the abnormal signaling pathways that drive cancer cell growth and proliferation.
2. Induction of Apoptosis: By blocking the survival signals of cancer cells, Imatinib Mesylate can induce apoptosis (programmed cell death) in these cells, thereby reducing the tumor burden.
3. Modulation of Immune Response: In addition to its direct effects on cancer cells, Imatinib Mesylate may also modulate the immune response by affecting the function of immune cells and reducing inflammation in the tumor microenvironment.